Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Bioincept LLC provides pre-implantation factor technologies as they relate to animal and human diagnostic and therapeutic health products. The company was founded by Dr. Jacqueline H. Barnea and Dr. Eytan R. Barnea in 2001 and is headquartered in Cherry Hill, NJ.

Zhaoke Pharmaceutical (Hefei) Co., Ltd., established on 1994-02-07, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Drug import and export;Disinfectant production(Free of Hazardous Chemicals);Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Disinfectant sales(Free of Hazardous Chemicals);Sales of Class I Medical Devices;Sales of Class II Medical Devices(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Mochida Pharmaceutical is a drug manufacturing company. Their pharmaceutical business aims to develop and market a broad spectrum of innovative new drugs. They also offer creates skin care products for the general public, and these are supplied through pharmacies, and drugstores.

Tianjin Institute of Pharmaceutical Research Co., Ltd. engages in the in the development of various new products such as innovative drugs, generic drugs, new preparations, traditional Chinese medicines, and biological drugs with particular emphasis on the engineering and industrialization of new technologies to meet drug registration requirements. The company was founded in 1959 and is headquartered in Tianjin, China.

Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland.

Mars, Inc. engages in the production of confectionery and animal food products. Its brands include M&M?s, Snickers, Twix, Milky Way, Dove, Pedigree, Whiskas, Extra, Skittles, Uncle Ben's, and Cocoavia. The company was founded by Franklin Clarence Mars in 1911 and is headquartered in McLean, VA.

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Accumetrics, Inc. developed, manufactured and marketed diagnostic testing and measurement instruments. The company was founded by Dennis Durbin and Robert S. Hillman in 1997 and was headquartered in San Diego, CA.

Ipca Laboratories is an international pharmaceutical company based in Mumbai, India. It produces Theo bromine, Acetylthiophene, and P-Bromo Toluene as Active Pharmaceutical Ingredients (APIs). Ipca sells these APIs and their intermediates world over. It produces more than 150 formulations that include oral liquids, tablets, dry powders, and capsules. The various kinds of drug intermediates that the company manufactures include Theo bromine, Acetylthiophene, and P- Bromo Toluene and promotes over 36 countries of Asia, Africa, CIS, and South America, including Cambodia, Kazakhstan, Kenya, Mauritius, Myanmar, Nigeria, Oman, Russia, Sri Lanka, Sudan, Tanzania, Ukraine, Vietnam and Yemen. The main activities of company are to produce and market pharmaceuticals and drugs. The various products of the company include formulations, drug intermediates, and active pharmaceutical ingredients (API).

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Kowa Co., Ltd. engages in trading of textiles, machinery, and construction materials. The company also manufactures and sells medicines, medical equipment, and energy saving products. It operates through the following business divisions: Pharmaceutical, Medical Device, Foods, General Trading, Lifestyle Business, and Hospitality. The company was founded on December 25, 1894 and is headquartered in Nagoya, Japan.

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Engages in priniting activities

Manufactures pharmaceuticals